RegFile AB

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

Trends and overview: ELRIG "Robotics and Automation"

Laboratories on the way to end-to-end automation: Robotics, artificial intelligence and automation technology boosted by pandemic

Skrubben bakom Nobelprisupptäckten

Det hör inte till vanligheterna att upptäckter som leder till Nobelpris görs på små biotechbolag. Ännu mer sällsynt är att arbetet bakom den prisbelönta forskni...

Sahlgrenska Science Park

LINK Medical Research

Merck Life Science A/S

Kompauto Nordic AB

Medicon Village Science Park

Bio-Works

Trumps ”lösning” på autismgåtan får forskare att skaka på huvudet

Användandet av paracetamol under graviditeten pekas av USA:s president Donald Trump ut som boven bakom autism, medan ett annat läkemedel med folinsyra – ett sla...

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

Novo Nordisk to invest billions in new quality control lab

Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2026)

ZEISS Connected Quality: One metrology hub

The new product family ZEISS CONNECTED QUALITY is the solution for quick and secure data exchange, quality management and efficient system monitoring.

Festo AB

Novo Nordisk establishes new factory in Denmark

Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.

Quotient Sciences Limited

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Affibody AB

Lonza

Galenica AB

Emerson